Details of the Drug
General Information of Drug (ID: DM2H9ND)
| Drug Name |
5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
3-(5-Mercapto-[1,3,4]oxadiazol-2-yl)-phenol; 3-(5-mercapto-1,3,4-oxadiazol-2-yl)phenol; 299465-12-6; 3-(5-sulfanyl-1,3,4-oxadiazol-2-yl)phenol; CHEMBL595356; 3-(5-Mercapto-1,3,4-Oxadiazol-2-Yl)-Phenol; AO-365/08835025; 5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione; 5-[3-Hydroxyphenyl]-1,3,4-oxadiazole-2(3H)-thione; NSC524085; AC1LF1GV; Oprea1_836042; CTK8F4715; CTK8A0072; MolPort-000-932-334; ZX-AN016552; ZINC1605604; BB_SC-06098; CCG-15357; STK506749; FCH842308; BDBM50320729; BBL000571; AKOS000564154; FCH2245445; NSC-524085
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 194.21 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.7 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


